MedTrace Logo

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

NCT02922764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2025-03-26

No results posted yet for this study

Summary

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.

Conditions

  • Endometrial Cancer
  • Endometrial Cancer Recurrent
  • Lung Cancer Recurrent
  • Lung Cancer
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Carcinoma

Interventions

DRUG

RGX-104

DRUG

Ipilimumab

DRUG

Docetaxel

DRUG

Pembrolizumab

DRUG

Carboplatin

DRUG

Pemetrexed

Sponsors & Collaborators

  • Inspirna, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Wasserman, MD · Inspirna, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2025-01-22
Completion
2025-01-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922764 on ClinicalTrials.gov